Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer. [electronic resource]
Producer: 20071002Description: 330-5 p. digitalISSN:- 0284-186X
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Capecitabine
- Denmark
- Deoxycytidine -- administration & dosage
- Disease Progression
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Epirubicin -- administration & dosage
- Esophagogastric Junction -- pathology
- Female
- Fluorouracil -- administration & dosage
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Severity of Illness Index
- Stomach Neoplasms -- drug therapy
- Survival Analysis
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.